Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+10.63%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$26.8B
AUM Growth
+$3.09B
(+13%)
Cap. Flow
+$1.27B
Cap. Flow
% of AUM
4.74%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
1,108
New
38
Increased
406
Reduced
634
Closed
28
Top Buys
| 1 |
Intel
INTC
|
+$208M |
| 2 |
Microchip Technology
MCHP
|
+$134M |
| 3 |
Qualcomm
QCOM
|
+$122M |
| 4 |
Analog Devices
ADI
|
+$122M |
| 5 |
Micron Technology
MU
|
+$113M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
+$326M |
| 2 |
NVIDIA
NVDA
|
+$116M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$78.6M |
| 4 |
iShares China Large-Cap ETF
FXI
|
+$72.7M |
| 5 |
KraneShares CSI China Internet ETF
KWEB
|
+$36.4M |
Sector Composition
| 1 | Technology | 47.46% |
| 2 | Financials | 9.33% |
| 3 | Healthcare | 6.2% |
| 4 | Consumer Discretionary | 3.62% |
| 5 | Energy | 2.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
PTC Therapeutics
PTCT
$4.63B
| $8.56M | 0.03% |
294,304
-45,659
| -13% | -$1.33M |
|
327
Valley National Bancorp
VLY
$5.99B
| $8.53M | 0.03% |
1,071,139
+259,891
| +32% | +$2.07M |
|
328
Raymond James Financial
RJF
$33.2B
| $8.5M | 0.03% |
66,197
-397
| -0.6% | -$51K |
|
329
Zoetis
ZTS
$66.2B
| $8.49M | 0.03% |
50,167
+1,209
| +2% | +$205K |
|
330
Alkermes
ALKS
$4.45B
| $8.49M | 0.03% |
313,523
-33,654
| -10% | -$911K |
|
331
Axos Financial
AX
$5.19B
| $8.48M | 0.03% |
156,878
-5,926
| -4% | -$320K |
|
332
Kymera Therapeutics
KYMR
$3.11B
| $8.48M | 0.03% |
210,861
+90,672
| +75% | +$3.65M |
|
333
Ultragenyx Pharmaceutical
RARE
$3.02B
| $8.47M | 0.03% |
181,484
-40,426
| -18% | -$1.89M |
|
334
Nasdaq
NDAQ
$54.3B
| $8.43M | 0.03% |
133,655
+12,991
| +11% | +$820K |
|
335
CRISPR Therapeutics
CRSP
$4.71B
| $8.42M | 0.03% |
123,574
-23,763
| -16% | -$1.62M |
|
336
Twist Bioscience
TWST
$1.46B
| $8.37M | 0.03% |
244,092
+14,483
| +6% | +$497K |
|
337
TG Therapeutics
TGTX
$5.05B
| $8.31M | 0.03% |
546,519
-24,607
| -4% | -$374K |
|
338
Corning
GLW
$64.2B
| $8.25M | 0.03% |
250,195
+10,163
| +4% | +$335K |
|
339
State Street
STT
$31.4B
| $8.21M | 0.03% |
106,222
-3,170
| -3% | -$245K |
|
340
SouthState Bank Corporation
SSB
$10.3B
| $8.19M | 0.03% |
96,322
-7,668
| -7% | -$652K |
|
341
Nuvalent
NUVL
$5.66B
| $8.16M | 0.03% |
108,668
-18,378
| -14% | -$1.38M |
|
342
Arcutis Biotherapeutics
ARQT
$2.11B
| $8.15M | 0.03% |
+822,461
| New | +$8.15M |
|
343
Beam Therapeutics
BEAM
$2.01B
| $8.07M | 0.03% |
244,354
-95,363
| -28% | -$3.15M |
|
344
Novavax
NVAX
$1.29B
| $8.04M | 0.03% |
1,682,659
+70,819
| +4% | +$339K |
|
345
Celldex Therapeutics
CLDX
$1.66B
| $8.03M | 0.03% |
191,415
+43,406
| +29% | +$1.82M |
|
346
Old National Bancorp
ONB
$8.81B
| $8M | 0.03% |
459,477
+5,335
| +1% | +$92.9K |
|
347
BioCryst Pharmaceuticals
BCRX
$1.68B
| $7.97M | 0.03% |
1,569,782
+614,195
| +64% | +$3.12M |
|
348
Kinder Morgan
KMI
$60.8B
| $7.96M | 0.03% |
433,886
-70,596
| -14% | -$1.29M |
|
349
Geron
GERN
$823M
| $7.96M | 0.03% |
2,411,211
+742,124
| +44% | +$2.45M |
|
350
Keros Therapeutics
KROS
$636M
| $7.91M | 0.03% |
119,511
+54,230
| +83% | +$3.59M |
|